Gujarat Themis Biosyn Limited Holds 45th AGM, Approves Financials, Director Re-appointment, Dividend, and Fund Raising
Gujarat Themis Biosyn Limited's 45th AGM on September 30, 2026, approved financial statements, director re-appointment, dividend, and commission payments. Shareholders also authorized availing loans, issuing shares via preferential allotment, and amending Articles of Association.
The approval of financial statements, dividend, director re-appointment, and especially the authorization for fund raising and loans to finance growth opportunities, are material events that will significantly impact the company's future operations and financial standing.
All resolutions, including financial adoption, director re-appointment, dividend declaration, and significant corporate actions like fund raising and loan approvals, were passed with overwhelming support, indicating strong shareholder confidence.
Gujarat Themis Biosyn Limited has announced the outcome of its 45th Annual General Meeting (AGM) held on Wednesday, 30th September, 2026. The meeting saw overwhelming support for all resolutions proposed.
The shareholders approved the Audited Financial Statements for the financial year ended 31st March, 2026, along with the Reports of the Board of Directors and Auditors. Additionally, Dr. Dinesh S. Patel was re-appointed as a Director, having retired by rotation and offered himself for re-appointment. The declaration of a dividend on equity shares for the financial year ended 31st March, 2026, was also approved.
Further, the shareholders ratified the remuneration of the Cost Auditor for the financial year 2026-27. Special resolutions were passed to approve the payment of commission to Dr. Dinesh S. Patel and Dr. Sachin D. Patel. The company also received approval to avail loans and guarantees from Promoters/Promoters Group to finance acquisition and growth opportunities. Shareholders also approved raising funds through a Preferential Issue and an amendment to the Articles of Association of the Company.
The voting results, including remote e-voting and voting during the AGM, indicated strong shareholder confidence in the company's management and future plans.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.